Abstracts Archive - Page 2122 of 2607 - ACR Meeting Abstracts

Abstract Number: 1670 • 2014 ACR/ARHP Annual Meeting
Characterization of Patients with Lupus Nephritis Included in a Large Cohort from the Spanish Society of Rheumatology Registry of Patients with Systemic Lupus Erythematosus
María Galindo Izquierdo¹, Esther Rodriguez-Almaraz¹, Sabina Perez², José M. Pego-Reigosa³, Jaime Calvo-Alen⁴, Francisco Javier López-Longo⁵, Iñigo Rúa-Figueroa⁶, Alejandro Olivé⁷, Víctor Martínez Taboada⁸, Paloma Vela Casasempere⁹, Mercedes Freire¹⁰, Javier Narváez¹¹, Antonio Fernandez Nebro¹², Jose Rosas¹³, Monica Ibanez Barcelo¹⁴, Esther Uriarte¹⁵, Eva Tomero¹⁶, Antonio Zea¹⁷, Maria Loreto Horcada¹⁸, Vicente Torrente¹⁹, Ivan Castellvi²⁰, Joan Calvet²¹, Raúl Menor Almagro²², Mª Angeles Aguirre²³, Enrique Raya²⁴, Elvira Diez Alvarez²⁵, Tomás Vázquez Rodríguez²⁶, Paloma García de la Peña²⁷, Atusa Movasat²⁸, José Luis Andreu²⁹, Patricia Richi³⁰, Carlos Marras Fernandez-Cid³¹, Carlos Alberto Montilla Morales³², Blanca Hernández-Cruz³³, José Luis Marenco de la Fuente³⁴, Marian Gantes³⁵, Eduardo Ucar³⁶, Juan J. Alegre³⁷, Javier Manero³⁸, Jesús Ibañez Ruán³⁹, Manuel Rodríguez-Gómez⁴⁰, Victor Quevedo⁴¹, José Hernández Beiraín⁴² and Lucía Silva Fernández⁴³, ¹Department of Rheumatology. Hospital Universitario 12 de Octubre, Madrid, Spain, ²Sociedad Española de Reumatología, Research Unit,, Madrid, Spain, ³Instituto de Investigación Biomédica de Vigo (IBIV), Vigo, Spain, ⁴Rheumatology Division, Sierrallana Hospital, Torrelavega, Spain, ⁵Rheumatology, Hospital Gregorio Marañon, Rheumatology, Hospital Gregorio Marañon, Madrid, Spain, ⁶Rheumatology, Hospital Doctor Negrin, Las Palmas de Gran Canaria, Spain, ⁷Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁸Rheumatology, Marqués de Valdecilla, Santander, Spain, ⁹Hospital General de Alicante, Alicante, Spain, ¹⁰Rheumatology, Hospital Universitario Juan Canalejo, La Coruña, Spain, ¹¹Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ¹²Rheumatology, Hospital Regional Carlos Haya, Biomedical Research Institute of Malaga (IBIMA), Malaga, Spain, ¹³Rheumatology, Hospital Marina Baixa. Villajoyosa, Villajoyosa, Spain, ¹⁴H. Son Llatzer, Palma de Mallorca, Spain, ¹⁵Rheumatology, Hospital de Donosti, San Sebastian, Spain, ¹⁶Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁷Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain, ¹⁸Rheumatology, Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁹Rheumatology, Hospital Moisès Broggi, Barcelona, Spain, ²⁰Unitat de Reumatologia., Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ²¹Hospital Parc Taulí, Barcelona, Spain, ²²Rheumatology, Hospital de Jerez, Jerez de la Frontera, Spain, ²³Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ²⁴Rheumatology, University Hospital San Cecilio, Granada, Spain, ²⁵Rheumatology, Leon Hospital, Leon, Spain, ²⁶Rheumatology, Hospital Lucus Augusti, Lugo, Spain, ²⁷Rheumatology, Hospital Norte Sanchinarro, Madrid, Spain, ²⁸Hospital Príncipe de Asturias, Immune System Diseases/Rheumatology department, Alcalá de Henares, Madrid, Spain, ²⁹Rheumatology, Hospital Puerta de Hierro, Madrid, Spain, ³⁰Hospital Infanta Sofía, Madrid, Spain, ³¹C/ Salvia 11, H. Arrixaca, Alicante, Spain, ³²Rheumatology Department, Hospital Virgen de la Vega, Salamanca, Spain, ³³Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain, ³⁴Hospital de Valme. Sevilla, Sevilla, Spain, ³⁵Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, ³⁶Hospital de Basurto, Rheumatology, Bilbao, Spain, ³⁷Rheumatology, Hospital Universitario Dr Peset, Valencia, Spain, ³⁸Ophthalmology and Rheumatology. Hospital Miguel Servet Zaragoza, Spain, Zaragoza, Spain, ³⁹POVISA, Rheumatology, Vigo, Spain, ⁴⁰Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ⁴¹Rheumatology, Hospital de Monforte, Lugo, Spain, ⁴²Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, ⁴³Rheumatology, Hospital Universitario de Guadalajara, Guadalajara, Spain
Background/Purpose To describe the profile of patients included in RELESSER with histologically confirmed lupus nephritis (LN). Methods RELESSER is a multicentre cross-sectional study, with information…
Abstract Number: 1669 • 2014 ACR/ARHP Annual Meeting
Validation of a Machine Learning Lupus Nephritis Decision Support Tool to Predict Complete Response to Therapy
Bethany Wolf¹, John Christian Spainhour¹, John Arthur², Michael Janech², Michelle Petri³, Adnan Kiani⁴ and Jim Oates^5,6, ¹Public Health Sciences, Medical University of South Carolina, Charleston, SC, ²Medicine, Medical University of South Carolina, Charleston, SC, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴1830 E Monument St, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁶Medical Service, Ralph H. Johnson VAMC, Charleston, SC
Background/Purpose .The American College of Rheumatology treatment guidelines for lupus nephritis (LN) recommend that induction therapy be changed when response to therapy has not occurred…
Abstract Number: 1668 • 2014 ACR/ARHP Annual Meeting
Identifying Patient Perceptions of Medication Decision Making Barriers in Minorities with Lupus Nephritis
Jasvinder A. Singh¹, Haiyan Qu², Jinoos Yazdany³, W. Winn Chatham², Maria Dall'era⁴ and Ricahrd Shewchuk⁵, ¹University of Alabama and VA Medical Center, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵University fo Alabama at Birmingham, Birmingham, AL
Background/Purpose: Studies suggest that adherence to medications for lupus nephritis is low. However, there are limited data available on the barriers that patients with lupus…
Abstract Number: 1667 • 2014 ACR/ARHP Annual Meeting
Probability of 3 and 6 Month Complete Response in Lupus Nephritis
Homa Timlin¹, Michelle Petri¹ and Laurence S Magder², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD

Background/Purpose: Lupus nephritis is a major cause of morbidity and mortality. The complete response rate is the most sensitive in detecting differences among therapeutic regimens.…
Abstract Number: 1666 • 2014 ACR/ARHP Annual Meeting
The Relevance of Urinary Podocyte Number and Urinary Podocalyxin Level with Response to Treatment and 1 Year Renal Prognosis in Systemic Lupus Erythematosus
Hiroshi Kajiyama¹, Keiju Hiromura², Daisuke Ikuma¹, Hidekazu Ikeuchi², Hiroyuki Kurosawa³, Yoshiaki Hirayama³, Fumio Gondaira³, Masanori Hara⁴, Yoshihisa Nojima² and Toshihide Mimura⁵, ¹Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, ²Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, ³Department of reagent research and development, Denka Seiken Co. Ltd., Niigata, Japan, ⁴Department of Pediatrics, Yoshida Hospital, Niigata, Japan, ⁵Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose Podocytes are glomerular visceral epithelial cells, whose number decrease due to death and/or detachment from capillary wall leads to severe proteinuria and end stage…
Abstract Number: 1665 • 2014 ACR/ARHP Annual Meeting
Efficacy Versus Safety of Prednisone in Lupus Nephritis Since 1988
Tanmayee Bichile¹, Laurence S Magder² and Michelle Petri³, ¹Rehumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose Morbidity and damage due to prednisone use in the treatment of SLE is recognized, but prednisone has been a requisite of lupus nephritis induction…
Abstract Number: 1664 • 2014 ACR/ARHP Annual Meeting
Novel Risk Factors for Systemic Lupus Erythematosus (SLE) Flares in Patients with End-Stage Renal Disease: Is SLE in Patients with End-Stage Renal Disease a “sleeping beauty”?
Jorge Alcocer-Varela¹, Mariana Quintanar², Javier Merayo-Chalico³, Ana Barrera-Vargas¹ and Diana Gómez-Martín¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose Renal involvement in systemic lupus erythematosus (SLE) is frequent, and a high percentage of patients (~15%) develop end-stage renal disease (ESRD) even with optimal…
Abstract Number: 1663 • 2014 ACR/ARHP Annual Meeting
Influence of Ethnicity on Efficacy of Current Immunosuppressive Protocols in Proliferative Lupus Nephritis
Angela Pakozdi¹, Ravindra Rajakariar², Michael Sheaff³ and Dev Pyne¹, ¹Rheumatology, Barts Health NHS Trust, London, United Kingdom, ²Renal Medicine, Barts Health NHS Trust, London, United Kingdom, ³Histopathology, Barts Health NHS Trust, London, United Kingdom
Background/Purpose Lupus nephritis (LN) is a major complication of systemic lupus erythematous (SLE) and prevalence is estimated to be 50-60%. Recently, variable responses to induction…
Abstract Number: 1682 • 2014 ACR/ARHP Annual Meeting
Mycophenolate Mofetil Versus Azathioprine in Scleroderma-Associated Interstitial Lung Disease: Results from the Australian Scleroderma Cohort Study
Claire Owen¹, Gene Ngian², Kathleen Elford², Owen Moore³, Mandy Nikpour³, Wendy Stevens³, Susanna Proudman⁴, Janet Roddy⁵, Jane Zochling⁶, Catherine Hill⁷, Peter Nash⁸, Allan Sturgess⁹ and Joanne Sahhar², ¹Rheumatology, Monash Health, Melbourne, Australia, ²Monash Health, Melbourne, Australia, ³St Vincent's Hospital, Melbourne, Australia, ⁴Royal Adelaide Hospital, Adelaide, Australia, ⁵Royal Perth Hospital, Perth, Australia, ⁶Department of Rheumatology, Menzies Research Institute Tasmania, Hobart, TAS, Australia, ⁷Queen Elizabeth Hospital, Adelaide, Australia, ⁸Sunshine Coast Rheumatology, Maroochydore, Australia, ⁹The St George Hospital, Sydney, Australia
Background/Purpose: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is common and when progressive, associated with significant morbidity and mortality. Cyclophosphamide is frequently used as first line…
Abstract Number: 1681 • 2014 ACR/ARHP Annual Meeting
Heart Transplantation in 6 Patients with Systemic Sclerosis and a Primary Cardiac Involvement
Alena Ikic¹, Emmanuel Chatelus², Eric Epailly³, Hélène Kremer³, Jean Sibilia², Jacques Gottenberg⁴, Sabine Pattier⁵, Erwan Flecher⁶, Céline Goeminne⁷ and Thierry Martin¹, ¹Strasbourg University Hospital, Strasbourg, France, ²Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ³Cardiology, Strasbourg University Hospital, Strasbourg, France, ⁴Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁵Cardiology, Nantes University Hospital, Nantes, France, ⁶Cardiac Surgey, Rennes University Hospital, Rennes, France, ⁷Cardiology, Lille University Hospital, Lille, France
Background/Purpose: There is no specific treatment for primary cardiac involvement in SSc. Even if heart transplantation is an option, only 1 case have been reported1.…
Abstract Number: 1680 • 2014 ACR/ARHP Annual Meeting
an Indirect Comparisons Analysis of Medications Used for Treatment of Raynaud’s Phenomenon
Sampath Manickam¹, Elie Donath², Sandeep Dayanand³ and Jonathan Greer⁴, ¹University of Miami Palm Beach Internal Medicine, West Palm Beach, FL, ²Internal Medicine, University of Miami Miller School of Medicine Palm Beach Regional Campus, Atlantis, FL, ³University of Miami Palm Beach Internal medicine, West palm beach, FL, ⁴Arthritis & Rheumatology Associates, Boynton Beach, FL
An Indirect Comparisons Analysis of Medications used for treatment of Raynaud’s phenomenonBackground/Purpose: There are several pharmacological treatments used for treatment of Raynaud’s phenomenon: calcium channel…
Abstract Number: 1679 • 2014 ACR/ARHP Annual Meeting
A Double Blind Randomized Control Trial of Oral Tadalafil in Interstitial Lung Disease of Scleroderma
Jyoti Parida¹, Alok Nath², Zafar Neyaz³ and Vikas Agarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Pulmonary Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Radiodiagnosis, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose We conducted a single center double-blind, randomized, placebo-controlled trial to determine the effects of oral Tadalafil on lung function and health-related symptoms in patients…
Abstract Number: 1678 • 2014 ACR/ARHP Annual Meeting
Initial Therapy with an Endothelin Receptor Antagonist Is Associated with Worse Outcomes in Patients with Systemic Sclerosis and Pulmonary Arterial Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Cohort
Matthew R. Lammi¹, Lesley Ann Saketkoo², Stephen C. Mathai³, Robyn T. Domsic⁴, Christine M. Bojanowski⁵, Virginia D. Steen⁶, Daniel E. Furst⁷ and Pharos Investigators⁸, ¹Section of Pulmonary and Critical Care Medicine, LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ³Medicine, Johns Hopkins University, Baltimore, MD, ⁴Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Internal Medicine and Pediatrics, LSU Health Sciences Center, New Orleans, LA, ⁶Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ⁷University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ⁸Georgetown University Medical Center, Washington, DC
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of mortality in systemic sclerosis (SSc). Although medications have improved their prognosis, optimal therapy remains undefined.…
Abstract Number: 1677 • 2014 ACR/ARHP Annual Meeting
Association of Gastrointestinal Symptoms with Immunosuppressant Use in the Prospective Registry of Early Systemic Sclerosis Cohort
Tracy M. Frech¹, Maureen Murtaugh², Ami A. Shah³, Jessica K. Gordon⁴, Victoria K. Shanmugam⁵, Robyn T. Domsic⁶, Monique Hinchcliff⁷, Faye N. Hant⁸, Shervin Assassi⁹, Virginia D. Steen¹⁰ and Dinesh Khanna¹¹, ¹Internal Medicine, Salt Lake City VAMC, Salt Lake, UT, ²Internal Medicine-Division of Epidemiology, University of Utah School of Medicine, SLC, UT, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Rheumatology, The George Washington University, Washington, DC, ⁶Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁷Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁸Dept of Medicine, Medical Univ of South Carolina, Charleston, SC, ⁹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ¹⁰Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ¹¹University of Michigan Health System, Ann Arbor, MI
Background/Purpose: The Prospective Registry of Early Systemic Sclerosis (PRESS) is a multicenter incident cohort study of patients with early diffuse cutaneous systemic sclerosis (dcSSc; <…
Abstract Number: 1658 • 2014 ACR/ARHP Annual Meeting
Renal Thrombotic Microangiopathy in Systemic Lupus Erythematosus: Novel Risk Factors and Clinical Outcomes
Ana Barrera-Vargas¹, Rodrigo Rosado-Canto², Javier Merayo-Chalico³, Jorge Alcocer-Varela¹ and Diana Gómez-Martín¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Thrombotic microangiopathy (TMA) is characterized by microvascular occlusion, systemic or intrarenal platelet aggregation and mechanical injury to erythrocytes. It is a pathological endpoint that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].